Global Interstitial Lung Disease Pipeline Expands to 120+ Therapies: Key FDA Updates and Clinical Advances Revealed by DelveInsight

DelveInsight, a leading life sciences market intelligence and consulting firm, announces the release of its latest publication, "Interstitial Lung Disease Pipeline Insight, 2025" offering an in-depth evaluation of the rapidly evolving therapeutic landscape for Interstitial Lung Disease (ILD). With more than 120+ companies developing 120+ therapeutic candidates, the ILD pipeline continues to expand with unprecedented scientific, clinical, and regulatory momentum.

The report delivers comprehensive covefrage of FDA approvals, ongoing clinical trials, emerging therapies, mechanism of action (MoA) innovations, route-of-administration trends, and strategic developments that are expected to transform ILD treatment outcomes in the years ahead.

Request for free sample report @ https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

A Global Push Toward Innovative Interstitial Lung Disease Therapies
According to DelveInsight's assessment, the ILD pipeline is marked by robust R&D activity from top biopharmaceutical companies such as AdAlta, Bristol-Myers Squibb, aTyr Pharma, Avalyn Pharmaceuticals, Beijing Continent Pharmaceutical, Regend Therapeutics, Reata Pharmaceuticals, FibroGen, PureTech Health, Bellerophon Pulse Technologies, OncoArendi Therapeutics, LTT Bio-Pharma, EmphyCorp, Genentech, Boehringer Ingelheim, Prometheus Biosciences, Bayer, Insmed, Roche, Ark Biosciences, Novartis, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics, Kadmon Pharmaceuticals, Taiho Pharmaceutical, Syndax Pharmaceuticals, Galecto Biotech, CSL Behring, AstraZeneca, and numerous emerging players.

These companies are actively developing therapies targeting fibrosis, inflammation, autoimmune pathways, immune modulation, and cellular repair reflecting the multidimensional nature of ILD pathogenesis.

Get a Free Sample PDF Report to know more about Interstitial Lung Disease Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Emerging Therapies Set to Shape the Future ILD Market
A diverse range of promising investigational therapies is advancing across clinical stages. Key emerging candidates include:
• AD-214,
• Abatacept,
• ATYR1923,
• Pirfenidone (inhalation),
• RO-0220912,
• Lung stem cell therapies,
• Bardoxolone methyl,
• Pamrevlumab,
• Deupirfenidone,
• INOpulse,
• OATD-01,
• LT0011,
• GDC-3280,
• BI 1015550,
• PRA023,
• Yifenidone,
• Riociguat,
• Treprostinil Palmitil,
• BMS 986278,
• Zinpentraxin alfa,
• LTI-03,
• HZN-825,
• ENV-101,
• PLN-74809,
• TAS-115,
• Axatilimab,
• GB0139,
• CSL312,
• Saracatinib,
and others.
These therapies from small molecules to cell and gene-based approaches-are projected to significantly influence the ILD market by offering targeted, effective, and safer treatment alternatives.

Recent Clinical Trial Developments Driving the ILD Landscape
• In February 2025, Boehringer Ingelheim's lung disease therapy, nerandomilast, has delivered positive outcomes in a Phase III trial, paving the way for potential approval in a second indication. Topline results from the FIBRONEER-ILD Phase III study (NCT05321082) showed that nerandomilast improved lung function in patients with progressive fibrosing interstitial lung diseases (PF-ILDs), excluding idiopathic pulmonary fibrosis (IPF). This follows an earlier successful trial focused on IPF, which supported the company's new drug application (NDA) submitted last year.
• March 2024: Boehringer Ingelheim launched a double-blind, randomized, placebo-controlled trial evaluating BI 1015550 for patients with progressive fibrosing ILDs (PF-ILDs) over at least 52 weeks.
• April 2024: Boehringer Ingelheim initiated INTENSE, a prospective observational study analyzing correlations between lung function decline and symptoms in CTD-associated PF-ILD patients treated with Nintedanib.
• January 2024: aTyr Pharma began a proof-of-concept clinical study evaluating Efzofitimod in systemic sclerosis-related ILD (SSc-ILD).
These ongoing and anticipated readouts are expected to significantly influence therapeutic strategies, regulatory decisions, and investment directions over the next few years.

Further Interstitial Lung Disease product details are provided in the report. Download the Interstitial Lung Disease pipeline report to learn more about the emerging Interstitial Lung Disease therapies at:
https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Understanding Interstitial Lung Disease: A Complex and Diverse Condition
Interstitial Lung Disease (ILD) comprises a broad array of disorders characterized by inflammation and progressive fibrosis of lung tissue, ultimately impairing oxygen exchange. Symptoms such as persistent dyspnea, chronic cough, and fatigue commonly worsen over time, significantly affecting patient quality of life.

ILD arises from multiple causes, including:
• environmental exposures (e.g., asbestos, silica),
• autoimmune conditions (e.g., rheumatoid arthritis, scleroderma),
• drug toxicity,
• genetic predispositions.

Diagnosis typically involves clinical evaluation, HRCT imaging, pulmonary function testing, and in select cases, lung biopsy. Treatment aims at controlling inflammation, slowing fibrotic progression, improving survival, and optimizing patient functioning.

As novel biomarkers, targeted pathways, and advanced inhaled delivery systems continue to emerge, the future of ILD management appears increasingly promising.

Route of Administration and Molecule Type Trends in the Interstitial Lung Disease Pipeline
DelveInsight's analysis categorizes ILD pipeline therapies by Route of Administration (RoA):
• Oral
• Intravenous
• Subcutaneous

and by Molecule Type, including:
• Small molecules
• Peptides
• Polymers
• Cell therapies
• Gene therapies
This diversity highlights the industry's focus on optimizing therapeutic delivery, patient compliance, and efficacy.

Interstitial Lung Disease Pipeline Therapeutics Assessment: A Detailed Breakdown
The Interstitial Lung Disease pipeline spans the full clinical spectrum:
• Phase III (Late-stage)
• Phase II (Mid-stage)
• Phase I (Early-stage)
• Preclinical and Discovery phases
• Discontinued & Inactive programs

The report evaluates each candidate across:
• mechanism of action,
• target pathways,
• clinical data,
• regulatory progress,
• development partnerships,
• molecule format,
• and intended route of administration.
Additionally, the report provides insights into collaborations, licensing activities, M&A deals, financing patterns, and academic partnerships driving innovation in this area.

Download Sample PDF Report to know more about Interstitial Lung Disease drugs and therapies-
https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Interstitial Lung Disease Market Outlook: Drivers, Barriers, and Unmet Needs
The global ILD market is poised for substantial growth due to:
Interstitial Lung Disease Market Drivers
• Rising prevalence of fibrosing ILDs worldwide
• Increasing clinical adoption of antifibrotic therapies
• Advancements in inhaled, targeted, and precision-based treatments
• Strong R&D investments and pipeline activity

Interstitial Lung Disease Market Barriers
• Diagnostic delays and clinical complexity
• High cost of antifibrotic and biologic therapies
• Limited long-term efficacy benchmarks for emerging drugs
• Variability in patient response

Interstitial Lung Disease Unmet Needs
• Earlier diagnosis tools
• Better-defined biomarkers
• Safer and more tolerable long-term treatment options
• Targeted therapies focusing on disease subtypes

To access detailed insights on ILD drugs, emerging therapies, and clinical developments:
Download the Sample PDF - Interstitial Lung Disease Pipeline Analysis - https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a premier Business Consulting and Market Research firm exclusively focused on the life sciences sector. The company provides end-to-end solutions that empower pharmaceutical companies with actionable intelligence, strategic insights, and data-driven decision support. Through a combination of deep domain expertise and robust analytical capabilities, DelveInsight enables organizations to accelerate growth, optimize performance, and strengthen their competitive positioning in the global healthcare ecosystem.

This release was published on openPR.